Abstract
Cellular senescence (CS) is recognized as one of the hallmarks of aging, and an important player in a variety of age-related pathologies. Accumulation of senescent cells can promote a pro-inflammatory and pro-cancerogenic microenvironment. Among potential senotherapeutics are extracellular vesicles (EVs) (40–1000 nm), including exosomes (40–150 nm), that play an important role in cell-cell communications. Here, we review the most recent studies on the impact of EVs derived from stem cells (MSCs, ESCs, iPSCs) as well as non-stem cells of various types on CS and discuss potential mechanisms responsible for the senotherapeutic effects of EVs. The analysis revealed that (i) EVs derived from stem cells, pluripotent (ESCs, iPSCs) or multipotent (MSCs of various origin), can mitigate the cellular senescence phenotype both in vitro and in vivo; (ii) this effect is presumably senomorphic; (iii) EVs display cross-species activity, without apparent immunogenic responses. In summary, stem cell-derived EVs appear to be promising senotherapeutics, with a feasible application in humans.
Author supplied keywords
Cite
CITATION STYLE
Rudnitsky, E., Braiman, A., Wolfson, M., Muradian, K. K., Gorbunova, V., Turgeman, G., & Fraifeld, V. E. (2024, August 1). Stem cell-derived extracellular vesicles as senotherapeutics. Ageing Research Reviews. Elsevier Ireland Ltd. https://doi.org/10.1016/j.arr.2024.102391
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.